Springworks Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It identifies pathways for drug development for patients with severe rare diseases and cancer. The firm's products include Nirogacestat, Mirdametinib and BGB-3245. The company was founded in August 2017 and is headquartered in Stamford, CT.
$69.35 -5.38 (-7.20%)
As of 03/04/2021 15:59:54 EST IEX book CBOE book
2021 © Stock Market MBA, Inc.